Alma, Michigan 48801


Purpose:

Acute Mountain Sickness (AMS) is a well-documented syndrome that affects 42% of non-acclimatized individuals traveling to altitudes above 10,000 feet. Decreased barometric pressure, which leads to low blood oxygen levels, is the primary casual factor of AMS. Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping. Moreover, when people travel to high altitude, cognitive performance and endurance exercise capacity are impaired. Therefore, the goal of this research is to identify effective pharmacological agents that will help reduce the symptoms of AMS and improve physical and cognitive performance at high altitude. The investigators will study the efficacy of the dietary supplement, quercetin, the drugs nifedipine (extended release) and methazolamide taken together, the drug metformin, and the drug nitrite in reducing symptoms of AMS and improving cognitive and exercise performance at high altitudes.


Criteria:

Inclusion Criteria: - healthy, - young (18-30 years old) men who can meet APFT requirements for special operation forces (SOF) training as outlined by the US Army (42 push ups, 53 sit-ups, 6 pull-ups, 2 mile run in < 15 min 54 s) Exclusion Criteria: - women; - smokers; - participants with diseases or disorders known to be affected by hypoxia or the drugs used in this study, such as hypotension, anemia, sickle cell trait or disease, and diabetes; - participants with a history of significant head injury, migraines or seizures; - participants taking any medication (over-the-counter or prescription) or herbal supplements; - participants with known flavonoid allergies; - participants with known allergies to metformin; - participants with known hypersensitivity reaction to nifedipine; - participants with known allergies to sulfonamide-based drugs; - participants with inability to be headache-free when consuming the amount of caffeine in two six ounce cups of coffee or less per day; - exposure to high altitude above 1000m in the previous three months; or - participants who have been on an airline flight over six hours (the lowered cabin pressure for an extended period of time approximates exposure to high altitude); - participants who are unable to achieve the minimum physical criteria required for SOF training


NCT ID:

NCT02463357


Primary Contact:

Principal Investigator
Robert Roach, PhD
University of Colorado Anschutz Medical Campus, Altitude Research Center

Robert Roach, PhD
Phone: 303-724-1671
Email: robert.roach@ucdenver.edu


Backup Contact:

Email: asubudhi@uccs.edu
Andrew Subudhi, PhD
Phone: 719-255-3938


Location Contact:

Alma, Michigan 48801
United States

John E Davis, PhD
Email: davisj@alma.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.